Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe study record’s update history now reflects a submission on November 11, 2026, and a posting on November 13, 2026, replacing the earlier dates.SummaryDifference0.1%

- Check11 days agoChange DetectedThe ClinicalTrials.gov record for the cabozantinib and nivolumab endometrial cancer study is displayed, with study details, results information, and supporting documents.SummaryDifference100%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedA banner announces NIH’s transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check60 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the preceding study details and document links with an access-denied message.SummaryDifference23%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.